Sign In
Buy IMRA
$17.45
-0.680 (-3.75%)
At Close: Jun 03, 2026
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
03:00am, Friday, 11'th Jun 2021
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687
2 Falling Knives to Catch
11:36am, Friday, 04'th Jun 2021
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor perfor
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
07:00am, Friday, 04'th Jun 2021
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial
Imara, Inc. (IMRA) CEO Rahul Ballal on Q1 2021 Results - Earnings Call Transcript
03:02pm, Tuesday, 11'th May 2021
Imara, Inc. (IMRA) CEO Rahul Ballal on Q1 2021 Results - Earnings Call Transcript
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
07:00am, Wednesday, 17'th Mar 2021
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower dos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
08:16pm, Sunday, 14'th Mar 2021
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advise
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
05:45am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
12:39pm, Friday, 05'th Mar 2021
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
Imara Reports Full Year 2020 Financial Results and Business Highlights
07:00am, Friday, 05'th Mar 2021
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
09:30pm, Friday, 26'th Feb 2021
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
07:00am, Friday, 19'th Feb 2021
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
07:00am, Wednesday, 20'th Jan 2021
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutic
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
05:21pm, Wednesday, 06'th Jan 2021
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap
Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
